SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 1,228.51 |
| Enterprise Value ($M) | 1,420.31 |
| Book Value ($M) | 646.90 |
| Book Value / Share | 10.31 |
| Price / Book | 1.90 |
| NCAV ($M) | -25.46 |
| NCAV / Share | -0.41 |
| Price / NCAV | -48.25 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.05 |
| Return on Assets (ROA) | -0.05 |
| Return on Equity (ROE) | -0.08 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.30 |
| Current Ratio | 2.48 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 582.02 |
| Assets | 1,254.39 |
| Liabilities | 607.49 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 358.71 |
| Operating Income | 166.87 |
| Net Income | 23.39 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 188.69 |
| Cash from Investing | -63.79 |
| Cash from Financing | -13.45 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock, Inc. | 14.00 | -15.06 | |
| 13D/A | Sarissa Capital Management LP | 4.70 | -43.37 | |
| 13G/A | Westfield Capital Management Co Lp | 0.00 | -100.00 | |
| 13G/A | Franklin Resources Inc | 7.10 | -30.88 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 99,284 | 563,874 | 17.61 | |
| 182,072 | 616,225 | 29.55 | |
| 188,936 | 651,400 | 29.00 | |
| 239,398 | 726,277 | 32.96 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| INDV – Indivior PLC | INNV – InnovAge Holding Corp. |
| INSM – Insmed Incorporated | INZY – Inozyme Pharma, Inc. |
| IOBT – IO Biotech, Inc. |